{
    "clinical_study": {
        "@rank": "65303", 
        "arm_group": [
            {
                "arm_group_label": "Sequence 1", 
                "arm_group_type": "Experimental", 
                "description": "3-way crossover of velusetrag or placebo"
            }, 
            {
                "arm_group_label": "Sequence 2", 
                "arm_group_type": "Experimental", 
                "description": "3-way crossover of velusetrag or placebo"
            }, 
            {
                "arm_group_label": "Sequence 3", 
                "arm_group_type": "Experimental", 
                "description": "3-way crossover of velusetrag or placebo"
            }, 
            {
                "arm_group_label": "Sequence 4", 
                "arm_group_type": "Experimental", 
                "description": "3-way crossover of velusetrag or placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a multicenter, randomized, double-blind, incomplete block, three period fixed\n      sequence crossover, multicenter, placebo-controlled study. The study will assess three oral\n      doses of velusetrag (5 mg, 15 mg, and/or 30 mg) or placebo, administered once daily in three\n      periods of 1-week duration each, with a 1-week washout period between treatment periods, in\n      subjects with diabetic or idiopathic gastroparesis.\n\n      Study 0093 will evaluate the effect of velusetrag in subjects with diabetic or idiopathic\n      gastroparesis by assessing changes in gastric emptying."
        }, 
        "brief_title": "A Multicenter, Phase II Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastroparesis", 
        "condition_browse": {
            "mesh_term": "Gastroparesis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Symptoms of gastroparesis (e.g., nausea, early satiety, fullness, bloating, upper\n             abdominal pain, retching or vomiting) for at least 3 months prior to Screening\n\n          -  Body Mass Index (BMI) between 18 and 35 kg/m2, inclusive\n\n          -  Gastroparesis Cardinal Symptom Index (GCSI-2W) composite score \u22652 and \u22644 at Screening\n\n          -  Delayed gastric emptying, defined as a gastric emptying half-time (GE t1/2) > 160\n             minutes as determined by [13C]-octanoate breath test, at Screening\n\n          -  Upper gastrointestinal (UGI) obstruction ruled out by endoscopy or other imaging\n             reasonably proximal to the diagnosis of gastroparesis\n\n        Exclusion Criteria:\n\n          -  Acute severe gastroenteritis within 2 weeks prior to Screening\n\n          -  History of gastric outlet obstruction\n\n          -  Prior history of gastric surgery, including but not limited to gastrectomy, gastric\n             bypass, gastric banding, pyloroplasty, vagotomy, or fundoplication\n\n          -  Recurrent vomiting, defined as vomiting more than 2 days per week\n\n          -  Hospitalization for treatment of gastroparesis or complications of diabetes within 4\n             weeks prior to Screening\n\n          -  Presence of thyroid dysfunction not controlled by treatment. Subjects with abnormal\n             thyroid stimulating hormone (TSH), hypothyroidism, or hyperthyroidism at Screening\n\n          -  If Type 1 or Type 2 diabetic, a glycosylated hemoglobin (HbA1c) level >10% or a\n             glucose > 250 mg/dL at Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718938", 
            "org_study_id": "0093"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "intervention_name": "velusetrag dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "intervention_name": "velusetrag dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "intervention_name": "velusetrag dose 3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence 1", 
                    "Sequence 2", 
                    "Sequence 3", 
                    "Sequence 4"
                ], 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Gastroparesis", 
            "Diabetic", 
            "Idiopathic", 
            "Delayed gastric emptying"
        ], 
        "lastchanged_date": "January 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85710"
                    }, 
                    "name": "Desert Sun Clinical Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90036"
                    }, 
                    "name": "Axis Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ventura", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93003"
                    }, 
                    "name": "Ventura Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jackson", 
                        "country": "United States", 
                        "state": "Mississippi", 
                        "zip": "39202"
                    }, 
                    "name": "GI Associates & Endoscopy Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mexico", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "65265"
                    }, 
                    "name": "Center for Digestive and Liver Diseases, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raleigh", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27612"
                    }, 
                    "name": "Wake Research Associates, LLC"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97210"
                    }, 
                    "name": "Northwest Gastroenterology Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "Digestive and Liver Disease Specialists"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase II Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Gastric emptying half time (GE t1/2)", 
            "safety_issue": "No", 
            "time_frame": "From baseline to week 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718938"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Duration of lag time to gastric emptying (tlag)", 
                "safety_issue": "No", 
                "time_frame": "From baseline to Week 5"
            }, 
            {
                "description": "Assess the safety and tolerability in subjects with diabetic or idiopathic gastroparesis", 
                "measure": "Vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to Day 49"
            }, 
            {
                "measure": "ECGs", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to Day 49"
            }, 
            {
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From baseline to Day 49"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Alfa Wassermann S.p.A.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}